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Abstract
Background: Unsafe injections, through infectious bodily fluids, are a major route of transmission for hepatitis B
and C. Viral hepatitis burden among people who inject drugs is particularly high in many Member States of central
and Eastern Europe while national capacity and willingness to address it varies greatly.
In 2013, the World Health Organization conducted a survey assessing national viral hepatitis efforts of 194 national
governments. Here, we present a sub-analysis of this global survey focusing on questions relating to people who
inject drugs in the WHO European Region.
Methods: The initial survey included 43 questions covering awareness, data, prevention, and screening and
treatment. It was sent in five languages to identified national focal points. This sub-analysis included 11 questions
and 53 Member States in the WHO European Region. Descriptive analyses of national activities are presented. As a
secondary outcome bivariate analyses of differences between Member States of the European Union (EU) and
European Free Trade Association (EFTA) compared to those not in said grouping are presented.
Results: Forty-four of the 53 Member States responded to the survey (response rate of 83%). More than three-
quarters reported offering publicly-funded treatment for HBV or HCV (82% and 80%, respectively), with a
significantly higher proportion of EU/EFTA Member States (P=0.004 and P=0.010, respectively). Half of Member
States (53%) reported the existence of a national policy for hepatitis prevention and control; however less than
one-third (27%) reported having written national strategies. Under half of the responding Member States reported
holding events for World Hepatitis Day 2012. One-fifth reported offering hepatitis B and C testing free of charge,
with less than one-third reportedly conducting regular serosurveys among people who inject drugs.
Conclusions: Findings highlight key gaps requiring attention in order to improve national policies and
programmes in the region and ensure an adequate response to injection drug use-associated viral hepatitis.
Further studies are required to assess quality and impact of national policies and services.
Introduction
Hepatitis B and C (HBV and HCV) are transmitted
through exposure to infectious bodily fluids. Transmission
may be through infected blood products or transfusions as
well as contaminated injections in medical settings and
among people who inject drugs (PWID).
Hepatitis B and C can produce acute illness ranging
from asymptomatic to fatal. Approximately 90% of HBV
infections are transient and patients recover fully [1]. In
persistent cases chronic infections occur, with patients
remaining infectious and developing liver cirrhosis, hepa-
tocellular carcinoma or both over a period of several
decades [2,3]. Modelling suggests that there were 240
million HBV surface antigen (HBsAg) positive persons in
2005 [4] and more than 185 million people were HCV
antibody-positive (anti-HCV) in 2010 [5]. Positive HBsAg
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corresponds to current infection, with antibodies to the
HBV core antigen (anti-HBc) and anti-HCV correspond-
ing to current or past infection for HBV and HCV,
respectively [2,3]. According to Global Burden of Disease
estimates, HBV and HCV together caused 1.3 million
deaths in 2010 [6];on par with other major infectious dis-
eases including malaria (causing 660,000 deaths in 2010)
[7], tuberculosis and HIV (causing 1.4 and 1.7 million
deaths in 2011, respectively) [8,9].
A safe and effective vaccine is available for hepatitis B
but not for hepatitis C. Both can be treated with antiviral
agents. Treatment for hepatitis B infection has been
shown to reduce the risk of hepatocellular carcinoma and
thereby mortality rates[10]. Hepatitis C is widely regarded
as curable, but treatment access barriers prevent many
people from benefiting from the available treatments
[11,12].
Unsafe injections, especially in the context of non-medi-
cal injection drug use, contribute disproportionately to the
transmission of HBV and HCV [13]. This is particularly
the case in Eastern Europe and Central Asia [14,15].
A 2011 study reported approximately ten million PWID
were anti-HCV positive and 6.4 million were positive for
anti-HBc with 1.2 million being HBsAg-positive globally.
The largest populations of HBsAg and HCV-positive
PWID were found to live in eastern Europe: 0.3 and
2.3 million, respectively [16].
A recent study reported PWID had the highest preva-
lence of HBC and HCV infections in countries of the
WHO European region outside of the European Union/
European Free Trade Association (EU/EFTA) [17]. Out-
side of the EU/EFTA, 21% of PWID were estimated to be
infected with HBV, while HBV prevalence in the EU/
EFTA was 3.7%. HCV prevalence in the EU/EFTA and
non-EU/EFTA regions were 47% and 43% respectively,
indicating that even in higher income European countries,
injection drug use leads to high prevalence rates of HCV.
Another study estimated that injection drug use as a risk
factor for hepatitis C accounted for 502,000 disability-
adjusted life years [18]. The 2013 European Drug Report
suggests the problem may be increasing in lower-income
states of the EU/EFTA [19]. Countries in eastern Europe
and central Asia have seen an increase in the population
of PWID as well as an accelerating HIV epidemic [20].
Increases in HIV co-infection with HBV and HCV among
PWID in these countries have led to viral hepatitis becom-
ing a major cause of death among HIV-positive people
[21]. Co-infection of HCV with tuberculosis is also com-
mon among PWID, with two thirds who develop tubercu-
losis also being anti-HCV positive [12]. In response, the
European Union adopted a Written Declaration on hepati-
tis B and C on 18 November 2013 calling for the recogni-
tion of these diseases as an urgent public health issue
requiring priority actions [22].
In order to take stock of national policy responses to
viral hepatitis worldwide, the World Health Organiza-
tion (WHO) in collaboration with the World Hepatitis
Alliance and the University of Copenhagen conducted a
survey of 194 WHO Member States in 2012–2013. This
study presents a sub-analysis of survey data from the
Member States of the WHO European Region, focusing
particularly on policy issues and activities that are rele-
vant to the prevention and control of viral hepatitis
among people who inject drugs.
Methods
The WHO hepatitis policy survey contains 43 questions,
most of which request information relating to the four
strategic axes outlined in the WHO Global Hepatitis Pro-
gramme Framework for Global Action (Table 1) [23].
The survey was written in English and piloted in 13
WHO Member States in 2012. Following the incorpora-
tion of feedback, the survey was translated into French,
Portuguese, Russian and Spanish. The final version of the
survey was distributed to identified focal points for viral
hepatitis in national ministries, departments of health or
related entities in 194 Member States. Selection of these
focal points was guided by direct communication with
government agencies as well as by input from WHO
regional and country offices.
Data collection took place between July 2012 and April
2013. Survey responses were e-mailed to study coordina-
tors at the University of Copenhagen, who compiled a
dataset of responses. Findings were reported in the
Global policy report on the prevention and control of viral
hepatitis in 2013 [24].
For the purpose of this sub-study, eleven survey ques-
tions relevant to PWID were selected (Additional file 1).
The analysis utilised survey responses of 53 Member
States comprising the WHO European Region. These
Member States were categorised as EU/EFTA and non-
EU/EFTA states for comparison. Thirty-one Member
States fell within the EU/EFTA area.1 Two additional
Member States under monetary agreements with the EU,
Andorra and San Marino, were included in the subgroup
given their geographic and socioeconomic proximity.
Twenty Member States were non-EU/EFTA states.2
Table 1 Strategic axes outlined in the Global Hepatitis
Programme framework
Axis Objective
Axis 1 Raising Awareness, Promoting Partnerships and Mobilizing
Resources
Axis 2 Evidence-Based Policy and Data for Action
Axis 3 Prevention of Transmission
Axis 4 Screening, Care and Treatment
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Descriptive statistics were created for the activities that
Member States reported in the survey. A secondary ana-
lysis compared the aforementioned subgroupings. As a
basic indication of differences between the EU/EFTA and
non-EU/EFTA regions, bivariate analysis using c2 testing
was performed. Bivariate analyses were two-tailed with a
significance level of 0.05. All subgroup findings are
reported, and subgroup differences that achieved statisti-
cal significance are reported with the p-value. An addi-
tional bivariate analysis compared the World Bank
income classifications of countries in the EU/EFTA and
non-EU/EFTA regions, using July 2012 definitions of
high-income, upper-middle-income, lower-middle-
income and low-income countries [25]. All analyses were




Forty-four of the 53 Member States in the WHO
European region replied to the survey and were included
in the analysis, a response rate of 83%. Twenty-eight of the
33 EU/EFTA Member States (85%) responded in compari-
son to 16 of 20 (80%) non-EU/EFTA Member States. The
majority (89%) of responding EU/EFTA Member States
were high-income countries, while only 6% of non-EU/
EFTA respondents were high-income countries (p<0.001)
(Table 2).
Table 3 reports the number and percentage of Mem-
ber States responding affirmatively to each survey ques-
tion included in this analysis.
National coordination
Twelve responding Member States (27%) reported hav-
ing a written national prevention and control strategy
which addressed injecting drug use. Six each of non-EU/
EFTA and EU/EFTA Member States (38% and 21%,
respectively) reported a written national strategy for
injection drug use (Table 4).
Thirty-two responding Member States (73%) reported
having some form of national prevention and control
programme which included activities addressing PWID
as a specific population. Ten non-EU/EFTA Member
States (69%) and 22 EU/EFTA Member States (79%)
reported programme activities addressing PWID.
Awareness-raising and evidence to guide policy
In the WHO European Region 17 Member States of the
44 (39%) who responded to the survey reported holding
events for World Hepatitis Day (WHD); of these,
7 Member States and an additional 3 Member States,
that did not hold events for WHD, reported organizing
viral hepatitis awareness campaigns (28%), other than
WHD, with messages on harm reduction. The number
of responding Member States reporting activities for
WHD was higher, 10 (36%), in the EU/EFTA subgroup-
ing, however a higher proportion of non EU/EFTA
Member States reported activities, 7 (44%). Similarly the
proportion of non EU/EFTA Member States reporting
awareness activities other than WHD was higher than
EU/EFTA, with 8% compared to 31%.
In the WHO European region, 12 responding Member
States (27%) reported conducting regular sero-surveys
among PWID; six each from EU/EFTA (21%) and non-
EU/EFTA (38%) subgroupings.
Prevention, testing and treatment
Twenty-five responding Member States (53%) reported
having a national policy for prevention of viral hepatitis
among PWID; nine (56%) of which were non-EU/EFTA
and 16 (57%) EU/EFTA. With regards to testing for HBV
and HCV, 20 (45%) Member States reported having univer-
sal testing free of charge, while 6 (14%) other Member
States reported having testing free of charge for PWID. Six
(38%) non-EU/EFTA and 14 (50%) EU/EFTA Member
States reported universal testing free of charge, with 2 (13%)
and 4 (14%) reporting testing free of charge for PWID.
Thirty-six (82%) responding Member States reported hav-
ing publicly funded HBV treatment. A significantly higher
proportion (p=0.004) of EU/EFTA Member States com-
pared to non-EU/EFTA Member States reported having
publicly funded treatment for HBV with 27 (96%) compared
to 9 (56%), respectively. Proportions of Member States in
the two subgroupings reporting drugs subsidised or on the
national essential-medicines list were similar for several
drugs; however Adefovir-dipivoxil and Entecavir were
reported more often (p=0.002) by EU/EFTA Member States
(20 (71%) and 19 (68%), respectively) compared to non-EU/
EFTA Member States (4(25%) and 3(20%), respectively).
Thirty-five (80%) responding Member States reported
having publicly funded treatment for HCV. A significantly
higher proportion (p=0.010) of EU/EFTA Member States
reported having publicly funded treatment for HCV,
26 (93%), compared to non-EU/EFTA Member States,
9 (56%). Significantly more EU/EFTA Member States
than non-EU/EFTA Member States reported having inter-
pheron alpha (p=0.050), Boceprevir (p=0.007) and







High income 1 (6) 25 (89) <0.001*
Upper middle-income 7 (44) 3 (11)
Lower middle-income 5 (31) 0 (0)
Lower income 3 (19) 0 (0)
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Table 3 Governments in the WHO European Region reporting activities addressing viral hepatitis by WHO Global
Hepatitis Programme strategic axis (N=44)
N=44
n (%)
Member States Reporting Activities
National
Coordination
Have viral hepatitis programme activities targeting PWID
as a specific population
32 (73) Armenia, Austria, Belarus, Belgium, Bulgaria, Croatia, Czech
Republic, Denmark, Finland, France, Ireland, Israel, Italy,
Kyrgyzstan, Latvia, Luxembourg, Malta, Montenegro,
Netherlands, Poland, Republic of Moldova, Russian Federation,
San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden,
Switzerland, The Former Yugoslav Republic of Macedonia,
Turkey, United Kingdom
Have a written national viral hepatitis prevention and
control strategy or plan which includes a component
relating to injection drug use
12 (27) Armenia, Austria, Czech Republic, Denmark, France, Israel,
Kyrgyzstan, Republic of Moldova, Russian Federation, Slovenia,
Turkey, United Kingdom
Axis 1 Held events for World Hepatitis Day 2012 17 (39) Albania, Armenia, Azerbaijan, Belarus, Bulgaria, Croatia, France,
Georgia, Italy, Latvia, Lithuania, Malta, Netherlands, Republic of
Moldova, Russian Federation , Slovenia, Sweden
Funded viral hepatitis awareness campaigns focusing on
harm reduction for PWID (other than World Hepatitis Day)
10 (23) Armenia, Belarus, Croatia, Netherlands, Republic of Moldova,
Russian Federation, Slovenia, Sweden, Turkey, United Kingdom
Axis 2 Conduct regular serosurveys among PWID 12 (27) Belarus, Croatia, Denmark, Finland, France, Montenegro,
Moldova, Russian Federation, Slovenia, Tajikistan, Ukraine,
United Kingdom
Axis 3 Have a national policy for prevention of viral hepatitis
among PWID
25 (53) Armenia, Austria, Belarus, Belgium, Bulgaria, Croatia, Czech
Republic, Denmark, France, Israel, Italy, Kyrgyzstan, Luxembourg,
Netherlands, Poland, Republic of Moldova, Russian Federation,
Slovenia, Spain, Sweden, Switzerland, The Former Yugoslav
Republic of Macedonia, Turkey, United Kingdom, Uzbekistan
Axis 4 Have HBV and HCV testing which is:
• Free of charge for all individuals 20 (45) • Albania, Austria, Azerbaijan, Belarus, Belgium, Croatia,
Denmark, Finland, France, Germany, Israel, Italy, Montenegro,
Republic of Moldova, Malta, San Marino, Slovakia, Spain,
Sweden, United Kingdom
• Free of charge for PWID 6 (14) • Bulgaria, Czech Republic, Latvia, Slovenia Turkey, The Former
Yugoslav Republic of Macedonia
Have publicly funded treatment for HBV 36 (82) Andorra, Armenia, Austria, Belarus, Belgium, Bulgaria, Croatia,
Cyprus, Czech Republic, Denmark, Estonia, Finland, France,
Germany, Hungary, Ireland, Italy, Latvia, Lithuania,
Luxembourg, Malta, Montenegro, Netherlands, Poland,
Republic of Moldova, Russian Federation, San Marino, Serbia,
Slovakia, Slovenia, Spain, Sweden, The Former Yugoslav
Republic of Macedonia, Turkey, United Kingdom
Have publicly funded treatment for HCV 35 (80) Andorra, Armenia, Austria, Belarus, Belgium, Bulgaria, Croatia,
Cyprus, Czech Republic, Denmark, Estonia, Finland, France,
Germany, Hungary, Ireland, Israel, Italy, Latvia, Lithuania,
Luxembourg, Malta, Montenegro, Netherlands, Poland,
Republic of Moldova, Russian Federation, San Marino, Serbia,
Slovenia, Spain, Sweden, The Former Yugoslav Republic of
Macedonia, Turkey, United Kingdom
Table 4 Governments in the WHO European region reporting activities addressing viral hepatitis by WHO Global








Have viral hepatitis programme activities address PWID as a specific population 10 (63) 22 (79) 0.512
Have a written national viral hepatitis prevention & control strategy which also
targets ID use
6 (38) 6 (21) 0.335
Axis 1 Held events for World Hepatitis Day 2012 7 (44) 10 (36) 0.765
Funded viral hepatitis awareness campaigns focusing on harm reduction for PWID
(other than World Hepatitis Day)
5 (31) 5 (18) 0.404
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Telaprevir (p=0.041); with 22 (79%) compared to 8 (50%),
15 (54%) compared to 2 (13%) and 14 (50%) compared to
3 (19%), respectively. Two Member States reported only
funding treatment for acute infections with two further
Member States only partially subsidising chronic treat-
ment [data not shown] for both HCV and HBV.
Discussion
This study is a sub-analysis of the WHO Global Hepatitis
Policy Survey, focusing on the countries of the WHO
European Region. It provides crucial insight into a central
public health problem in the region: very high prevalence
of viral hepatitis among PWID. Given the extent of the
problem, and a previous reticence to address it, it was
encouraging to note that Member States in the region
are willing to engage with WHO in order to address viral
hepatitis.
Various means of addressing viral hepatitis among PWID
at national and global levels exist. A WHO guidance docu-
ment presented five recommendations on the prevention
of viral hepatitis B and C among PWID in 2012 [26].
These included offering a rapid HBV vaccination regimen,
offering incentives to increase uptake and completion of
the HBV vaccination schedule, suggestions that needle and
syringe programmes provide low dead-space syringes for
distribution to PWID, not using psychosocial interventions
for PWID and instead to offer peer interventions for reduc-
tion of viral hepatitis incidence. These recommendations
can be categorised into the four strategic axes of the WHO
Global Hepatitis Programme (Table 1) outlined in the Fra-
mework for Global Action [23]. It is essential that policy
responses encompass aspects of these four strategic areas.
A notably positive finding is that over half of responding
Member States reported having a national policy for the
prevention of viral hepatitis among PWID, as compared to
37% globally [24]. A higher proportion of Member States
reported having programme activities addressing viral
hepatitis among PWID; seven Member States reported
activities even in the absence of national policies. Less pro-
mising is the finding that less than one-third of Member
States reported having written national viral hepatitis pre-
vention and control strategies that include a component
addressing PWID. Such documents are the foundation for
strong, evidence-based, national response to the complex
array of factors contributing to the hepatitis epidemic
among PWID. Further investigation is required to assess
the structure and content of national programme activities
and other efforts, including the work of nongovernmental
organisations.
In light of new drug therapies, it is particularly promis-
ing that more than 80% of Member States offer publicly
funded treatment for HBV and HCV. Experts predict
that in the next 2-5 years, 90% of HCV infections will be
curable with an all-oral, once-daily, 12-week regimen of
safe drugs as compared with the current regimen requir-
ing 24 to 48 weeks of weekly injections and results in
Table 4 Governments in the WHO European region reporting activities addressing viral hepatitis by WHO Global
Hepatitis Programme strategic axis and EU/EFTA membership (N=44) (Continued)
Axis 2 Conduct regular serosurveys among PWID 6 (38) 6 (21) 0.639
Axis 3 Have a national policy for prevention & control of viral hepatitis among PWID 9 (56) 16 (57) 0.954
Axis 4 Have HBV & HCV testing which is:
• Free of charge for all 6 (38) 14 (50) 0.569
• Free of charge for PWID 2 (13) 4 (14) 0.423
Have publicly funded treatment for HBV 9 (56) 27 (96) 0.004*
HBV Drugs on national essential medicines list or subsidized by government:
• Interferon alpha 12 (75) 22 (79) 0.786
• Pegylated interferon 11 (69) 22 (79) 0.469
• Lamivudine 13 (81) 24 (86) 0.697
• Adefovir dipivoxil 4 (25) 20 (71) 0.003*
• Entecavir 3 (20) 19 (68) 0.002*
• Telbivudine 4 (25) 13 (46) 0.160
• Tenofovir 8 (50) 19 (68) 0.242
Have publicly funded treatment for HCV 9 (56) 26 (93) 0.010*
HCV Drugs on national essential medicines list or subsidized by government:
• Interferon alpha 8 (50) 22 (79) 0.050*
• Pegylated interferon 12 (75) 23 (82) 0.572
• Ribavirin 14 (88) 24 (86) 0.868
• Boceprevir 2 (13) 15 (54) 0.007*
• Telaprevir 3 (19) 14 (50) 0.041*
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cure-rates of 45-80% [27]. Indeed, oral only treatment
attained a sustained viral response in 8 weeks in a trial of
high-risk HCV-patients [28], promising results for
addressing adherence and treatment-cost. Recent WHO
guidelines indicate treatment of HCV among PWID is
efficacious, cost-effective and may be effective as preven-
tion due to the reduction in transmission [12]. Chronic
HBV therapy is also improving with drug regimens
becoming more potent and easier to administer [29].
However, the persistence of treatment access barriers
means that treatment uptake and adherence among
PWID remains low [13,14,23]. Major barriers to treat-
ment include stigmatisation and systematic exclusion of
former or current PWID in some nations, along with
criminalisation [13,14,30,31]. Indeed, one Member State
reported that injection drug use is a contraindication for
beginning treatment, with several Member States only
funding acute treatment. Results should be interpreted
with caution where governments fund non-specific treat-
ment, which means treating symptoms rather than the
disease. In situations where specific treatment is funded,
further investigation is warranted to clarify whether treat-
ment funding policies are comparable across the region.
Gaps in funding specific treatment is exemplified by
results from non-EU/EFTA Member States, where a
large proportion report funding Interferons but not full
treatment regimens for HCV; however differences in
public funding may be attributable to national income
distribution differences between EU/EFTA and not.
Given the low socio-economic status of many PWID,
beyond funding treatment, government policies which
support and encourage cost-effective prevention pro-
grammes, such as vaccination and needle exchange pro-
grammes, are essential [13,14,32]. These need to be
supplemented by alternative intervention methods which
have been shown to be effective. In example removing
users from the PWID population [32] or transitioning to
non-injecting drug use [33]. Coupling these with initiatives
to enable access to affordable, quality screening and treat-
ment is key to curtailing the epidemic among PWID.
Prevention and access campaigns are increasingly impor-
tant to control unsafe injection-associated infections, as
the illicit nature and associated marginalisation of PWID
populations make them hard to reach for conventional
healthcare providers [14,34]. A recent review outlines the
need for social interventions relating to housing, stigma
reduction and systemic changes in policy and health care
delivery in order to improve access and uptake of hepatitis
C treatment among PWID [35]. Social change can be
initiated through policy and legislation. Reports suggest
that activities to address unsafe injection-associated infec-
tious disease among PWID have been implemented to
varying degrees by Member States in the region [9,14,24].
Epidemiological data detailing prevalence by popula-
tion-groups is vital for both policy-makers and healthcare
planners to assess intervention costs and ensure evi-
dence-based planning of responses. Such data can be
gathered, among other methods, from serosurveys as well
as centralised reporting of screening results. Screening is
also essential for identifying those who would benefit
from treatment and thereby reduce the personally and
monetarily, costly sequelae of infection [36,37]. Thus it is
in the interest of policy makers to support this evidence
base. High-quality data from hepatitis prevalence studies
are sparse in Eastern Europe and Central Asia [38].
Findings regarding national serosurveys are worrying,
with under one-third of Member States conducting them
regularly. Similar to the ~40% that reported free testing,
globally [24]. Surprisingly, a higher proportion, though
not statistically significant, of non-EU/EFTA Member
States reported conducting regular serosurveys; it would
be expected that EU/EFTA members would have such
surveillance methods in place, due to support by the Eur-
opean Centre for Disease Prevention and Control. It is
important to present such data to policy-makers in order
to ensure that decisions are taken based on representative
data. Though not definitive, this lack of data may explain
our finding of Member States reporting programme
activities not being based on written strategies.
Less than half offer HBV and HCV testing free of
charge; with a non-significantly higher proportion of EU/
EFTA Member States reporting publicly funded testing.
Funding differences may be attributable to the income dis-
tribution differences between EU/EFTA and non-EU/
EFTA. Details of which screening tests were funded could
not be gleaned from the survey and future studies may
benefit from investigating this detail. Facilitating access to
screening services is particularly pertinent when dealing
with marginalised populations such as PWID.
Under two fifths of responding Member States reported
holding events for World Hepatitis Day 2012 (28 July).
This is troubling, as awareness-raising is such a vital first-
step in controlling these diseases, particularly among
PWID, where educational messages on harm reduction
have been shown to be effective[19].
An argument could be made for policies to be focused
on any of the four areas. However, as emphasis on one
area may impact the remaining three, it is important that
efforts in all four areas are scaled up in unison to address
viral hepatitis effectively. A recent review details the need
for a combination of preventative efforts to address
worldwide burden [30].
Our study provides valuable information to policy-
makers and health analysts in the WHO European
region on the extent to which viral hepatitis is being
addressed among PWID. It is anticipated that policy
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makers will utilise this information in order to compare
progress of Member States in the region with the intent
of identifying areas which could be improved and
inform further investigation in to national programmes
in their respective countries.
Several limitations may have influenced study findings.
Survey questions sought to document the existence of
national policies, strategies and programmes without
seeking to assess the extent to which they are being
implemented. The survey also did not yield information
on quality or impact of programmes. To this end, further
investigations need to be undertaken to verify Member
States reports and to assess how policies, strategies and
programmes are contributing to beneficial outcomes.
Patient groups and other nongovernmental organisations
have an important role to play in these investigations;
this study could have benefited from input by said parties
as well as civil society groups.
Linguistic and semantic considerations should also be
highlighted. As the survey was limited to the aforemen-
tioned five languages, response rates and a thorough, clear
understanding of survey questions may have been affected.
Ambiguity as well as variations in the interpretation of
questions by region or culture may have also led to differ-
ential understanding of, and responses to, survey questions.
In addition, data included here are those reported by
identified focal-points from each Member State. It was not
possible to verify the data submitted prior to writing this
manuscript. Further studies are currently being underta-
ken by the WHO global hepatitis programme to assess the
quality and content of national programmes. Bivariate ana-
lyses conducted are basic indications with many potential
confounders and do not describe definitive or causal asso-
ciations, particularly due to low sample-size. Further stu-
dies would benefit from investigating reasons behind
differences in national policies and activities.
In summary, this sub-analysis highlights gaps which
require attention, particularly with regards to the evi-
dence base and awareness, in order to improve policies
and programme activities addressing viral hepatitis
among PWID in the European region. Further studies
are urgently needed to detail areas requiring policy
attention and to ensure an effective response to this glo-
bal health problem.
Additional material
Additional file 1: Survey instructions and questions selected for this
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